DD Stock Forecast & Price Target

DuPont de Nemours is viewed positively because its portfolio transformation has improved the quality of earnings, with management and analysts pointing to stable EPS growth, continued organic improvement, and over 100% FCF conversion in Q2. The company’s healthier balance sheet, supported by about $0.7B in cash, roughly $3.2B in gross debt, and about $5B of debt repayment after the Q divestiture, creates room for buybacks, deleveraging below its <2.0x net debt-to-EBITDA target, or bolt-on M&A. Fundamental upside also comes from higher-margin end markets, as Healthcare technologies is set up for about hsd% organic growth and Water & Protection should deliver msd% growth, while valuation may rerate as it shifts toward a multi-industrial profile.

DuPont de Nemours is viewed negatively because its operating outlook remains exposed to a slower-than-expected recovery in China and North America, ongoing weakness in electronics and construction, and execution risk around synergy realization and the planned electronics spin. The company’s downside case already assumes delayed synergies and continued weakness, with 2026E downside EBITDA of $2.17 and only limited tariff exposure, since China/Hong Kong revenue is about 19% and the China Tyvek probe is roughly 0.7% of sales. Even so, repeated spin-strategy delays or integration missteps could keep margins and valuation under pressure, especially if healthcare and water do not offset cyclical weakness fast enough.